GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2015
Hodgkin lymphoma, version 2.2015.
Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Scientific reports · 2017Pooled it
- Trial
- Trial
- Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.British journal of haematology · 2025Review
- The Role of Artificial Intelligence and Radiomics in the Management of Lymphomas by PET/CT: The Clairvoyance in Clinic.Cancer management and research · 2025Review
- Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities.PET clinics · 2024Review
- Intramuscular lymphoma: uncommon presentation of Hodgkin's disease.BMJ case reports · 2020Article
- Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.British journal of clinical pharmacology · 2019Article
- Long-Term Survival Rates of Patients with Stage III-IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984-2013.The oncologist · 2018Article
- Article
- The role of FDG-PET in Hodgkin lymphoma.Contemporary oncology (Poznan, Poland) · 2017Review
- Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2016Review
- Self-collected dried blood spots as a tool for measuring ovarian reserve in young female cancer survivors.Human reproduction (Oxford, England) · 2016Article
- Recent advances in the management of Hodgkin lymphoma.F1000Research · 2016Review
- Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.Current treatment options in oncology · 2015Review
- Severe neurotoxicity due to Vinblastine in Hodgkin lymphoma.South Asian journal of cancer · 2014Article
- Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 2 countries.
Funding
Abstract
Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.